Fu Gui

Affiliations: 
2012-2016 School of Life Sciences, Xiamen University 
Google:
"Fu Gui"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Tsujino T, Takai T, Hinohara K, et al. (2023) CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature Communications. 14: 252
Zhang CS, Li M, Wang Y, et al. (2022) The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. Nature Metabolism
Miao C, Tsujino T, Takai T, et al. (2022) loss overrides PARP inhibitor sensitivity driven by loss in prostate cancer. Science Advances. 8: eabl9794
Lu Y, Fan Z, Zhu SJ, et al. (2021) A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. Embo Molecular Medicine. e14296
Li W, Ni H, Wu S, et al. (2020) Targeting RIPK3 oligomerization blocks necroptosis without inducing apoptosis. Febs Letters
Gui F, Jiang J, He Z, et al. (2019) A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk mutation in B-cell malignancies. British Journal of Pharmacology
Jiang J, Gui F, He Z, et al. (2016) Targeting BRK-positive breast cancers with small molecule kinase inhibitors. Cancer Research
Wang Y, Qi S, Zhan Y, et al. (2015) Aspertetranones A-D, Putative Meroterpenoids from the Marine Algal-Associated Fungus Aspergillus sp. ZL0-1b14. Journal of Natural Products
See more...